Broadwood opposes Alcon's STAAR Surgical acquisition bid

Broadwood Partners, which owns 27.5% of STAAR Surgical Company (NASDAQ: STAA), issued a statement opposing Alcon Inc.'s (NYSE: ALC) proposed acquisition of the medical device company.

Neal C. Bradsher, Broadwood's founder and president, criticized Alcon's investor presentation regarding the transaction, calling it "replete with fallacious arguments and baseless claims." Broadwood continues to urge STAAR shareholders to vote against the proposed deal using its green proxy card.

The investment firm stated that STAAR's board does not need Alcon's permission to remain independent or conduct a strategic alternatives process. Broadwood noted that STAAR shareholders and three proxy advisors have reacted negatively to the timing, process and price of the proposed transaction.

Bradsher highlighted Broadwood's investment track record, stating that $1 million invested with the firm at the beginning of 2000 is now worth more than $47 million. He contrasted this with Alcon's performance since its 2019 spinout, noting that Alcon's stock trades at approximately $75 per share.

A special meeting of STAAR shareholders is scheduled for October 23, 2025, to vote on the acquisition proposal. The meeting had previously been adjourned and postponed by STAAR's board.

Broadwood also indicated it intends to file a separate proxy statement to solicit votes for removing members of STAAR's board at a future shareholder meeting, which would be distinct from the acquisition vote.

The information is based on a press release statement from Broadwood Partners.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Robinhood experiences service disruptions amid record traffic
• Newmont receives 13.3% stake in LunR Royalties through dividend distribution